Compare Snap On Incorporated (SNA) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs 10X Genomics Inc — how do they compare? Snap On Incorporated trades at $402.3 (market cap $21.06B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: Snap On Incorporated is far larger — about 3.8× 10X Genomics Inc's market cap, and Snap On Incorporated pays a 2.4% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SNA | TXG | |
|---|---|---|
Market Cap | $21.06B | $5.48B |
Sector | Technology | Health |
52-Week High | $414.97 | $45.80 |
52-Week Low | $317.79 | $11.34 |
Enterprise Value | $20.58B | $5.02B |
Dividend Yield | 2.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong 2025 results with $5.16B revenue and $1.02B net income, maintaining robust profitability margins. Recent strategic acquisitions like Diesel Laptops for $100M aim to expand its heavy-duty diagnostics capabilities, supporting future growth.
The outlook is positive given solid fundamentals and analyst support, but risks include potential margin pressures and reliance on automotive demand. With 64.71% of analysts rating it a buy and a dividend yield supported by recent declarations, SNA presents a stable investment opportunity tempered by industry cyclicality.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
